Menu Trigger
Jason Damiano, Ph.D.
PRZEMYSLAW (MIKE) SAPIEHA Przemyslaw (Mike) Sapieha
Anirvan Ghosh, PH.D.

Chief Executive Officer

Anirvan joined UNITY as CEO in March 2020. Prior to joining UNITY, he served as senior vice president and head of research and early development at Biogen. During his tenure at Biogen, Anirvan led a team of 350 scientists and clinicians responsible for preclinical, and clinical Phase 1 and Phase 2 studies in all of Biogen’s disease areas and led a marked expansion of its early clinical portfolio. Between 2017 and 2020, ten assets advanced from Research to Development and several reported positive proof of concept studies and are now in pivotal registration-enabling clinical trials. Anirvan was also involved in expanding the portfolio through key partnerships, including acquisition of early stage assets in Alzheimer’s Disease, Schizophrenia, and Ophthalmology, and several multi-asset platform collaborations.

Prior to joining Biogen, Anirvan served as vice president and global head of neuroscience discovery and biomarkers at Roche. Previously he also held academic appointments at The Johns Hopkins School of Medicine and the University of California, San Diego. Anirvan received his BS in physics from California Institute of Technology and his Ph.D. in neuroscience from Stanford University. He completed his postdoctoral work at Harvard Medical School. The impact of his scientific contributions is reflected in over 100 scientific publications in top-tier journals, including Science and Nature. He has been a recipient of numerous awards, and as a recognized scientific leader he has chaired leading scientific congresses including Gordon Research Conferences and Cold Spring Harbor Meetings.